Compositions and processes for engineering ureteric bud kidney tissues and in-vitro compositions thereof
AssigneeTrestle Biotherapeutics, Inc.
InventorsBenjamin Shepherd, Alice Chen, J. William Higgins, III
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions comprising engineered ureteric bud kidney tissues and methods of making lumenized ureteric bud kidney tissues. Also provided herein are in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Methods of making the compositions and in vitro kidneys and uses thereof are disclosed herein. In some aspects, provided herein are methods for generating a lumenized kidney tissue having a spatially-controlled 3-dimensional (3D) tubular architecture in vitro.
Claims30
A method for generating a lumenized kidney tissue having a spatially-controlled 3-dimensional (3D) tubular architecture in vitro, the method comprising:
- (a) generating a plurality of ureteric bud (UB) kidney tissues from a population of Wolffian duct progenitor cells that express CXCR4, cKit, or a combination thereof;
- (b) spatially arranging the plurality of UB kidney tissues in a sequential configuration and in a proximity sufficient to form fused UB kidney tissues that are contiguously fused from at least one connecting point;
- and
- (c) culturing the fused UB kidney tissues in a branching medium, thereby forming a lumenized kidney tissue having a spatially-controlled 3D tubular architecture,
- wherein the lumenized kidney tissue upon contact with a fluid facilitates fluid flow through the spatially-controlled 3D tubular architecture.
An in vitro composition comprising:
- an in vitro-differentiated human kidney tissue comprising a population of human nephron progenitor cells (NPCs) connected to a population of fragmented ureteric bud (UB) kidney tissues,
- wherein:
- the in vitro-differentiated human kidney tissue comprises a collecting duct,
- and the in vitro-differentiated human kidney tissue comprises two or more markers selected from:
- LRP2, GATA3, MAFB, EpCAM, PODXL and CK8.
An in vitro-differentiated human kidney tissue comprising:
- a population of human nephron progenitor cells (NPCs) connected to a population of fragmented ureteric bud (UB) kidney tissues differentiated from Wolffian duct progenitor cells,
- wherein the in vitro-differentiated human kidney tissue comprises repeating units of nephric-ureteric connections in a sequential configuration.
A method of generating a lumenized in vitro-differentiated human kidney tissue, the method comprising:
- (a) differentiating a population of human induced pluripotent stem cells (iPSCs) to a population of Wolffian duct progenitor cells;
- (b) isolating Wolffian duct progenitor cells expressing a marker selected from CXCR4, cKit, or a combination thereof;
- (c) contacting the Wolffian duct progenitor cells isolated from (b) with a first cell culture medium and culturing the Wolffian duct progenitor cells for at least 48 hours in static cell culture conditions, wherein the first cell medium comprises:
- retinoic acid, fibroblast growth factor 9 (FGF9), LDN193189, CHIR99021, fibroblast growth factor 1 (FGF1), glial-derived neurotrophic factor 1 (GDNF), Y27632, a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, or a combination thereof;
- (d) arranging the Wolffian duct progenitor cells in a sequential configuration and in a proximity sufficient to form fused UB kidney tissues that are contiguously fused from at least one connecting point;
- and
- (e) culturing the fused UB kidney tissues in a branching culture medium for at least 48 hours to form a lumenized in vitro-differentiated human kidney tissue, wherein the branching culture medium comprises retinoic acid, RSPO1, a neurotrophic factor, a fibroblast growth factor, a bone morphogenetic pathway inhibitor, an extracellular matrix, or a combination thereof.
Dependencies are inferred from the claim text.